Clinical Trial Update: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating KRT-232 in combination with acalabrutinib for relapsed/refractory DLBCL and CLL; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• KRT-232

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN